Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies

Biologicals

Volumn 42, Issue 5, 2014, Pages 237-259

  Kumru, Ozan S ^a   Joshi, Sangeeta B ^a   Smith, Dawn E ^b   Middaugh, C Russell ^a   Prusik, Ted ^b   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b Temptime Corporation   (United States)

Author keywords

Adjuvant; Cold chain; Formulation; Lyophilization; Stability; Vaccine

Indexed keywords

HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES VACCINE; POLIOMYELITIS VACCINE; ANTIGEN; VACCINE;

ANALYTIC METHOD; ANTIGEN STRUCTURE; BIOASSAY; DRUG DESIGN; DRUG FORMULATION; DRUG MONITORING; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; FREEZE DRYING; HUMAN; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; REVIEW; SHELF LIFE; VACCINE INSTABILITY; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; COLD; IMMUNOLOGY; MEDICINAL CHEMISTRY; PROCEDURES; STANDARDS; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CHEMISTRY, PHARMACEUTICAL; COLD TEMPERATURE; DRUG STABILITY; DRUG STORAGE; HEPATITIS B VACCINES; HUMANS; INFLUENZA VACCINES; MEASLES VACCINE; POLIOVIRUS VACCINES; VACCINES;

EID: 84908205303     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2014.05.007     Document Type: Review

References (207)

1. Centers for Disease C, Prevention Ten great public health achievements-United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999, 48:241-243.
2. Maurice J.M., Davey S. State of the world's vaccines and immunization 2009, World Health Organization. http://www.who.int/immunization/sowvi/en/.
3. Frontières M.S. The Right Shot: Extending the reach of affordable and adapted vaccines http://www.msfaccess.org/content/rightshot2012.
4. Kristensen D., Zaffran M. Designing vaccines for developing-country populations: ideal attributes, delivery devices, and presentation formats. Proced Vaccinol 2010, 2:119-123.
5. Plotkin S.A. Six revolutions in vaccinology. Pediatr Infect Dis J 2005, 24:1-9.
6. Complete list of vaccines licensed for immunization and distribution 2013, US Food and Drug Administration. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833.
7. Burke C.J., Hsu T.A., Volkin D.B. Formulation, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst 1999, 16:1-83.
8. Brandau D.T., Jones L.S., Wiethoff C.M., Rexroad J., Middaugh C.R. Thermal stability of vaccines. JPharm Sci 2003, 92:218-231.
9. Milstien J., Kartoglu U. Temperature sensitivity of vaccines 2006, World Health Organization, Geneva.
10. Matthias D.M., Robertson J., Garrison M.M., Newland S., Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007, 25:3980-3986.
11. Chen D., Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev Vaccines 2009, 8:547-557.
12. Kristensen D. Summary of stability data for licensced vaccines 2012, PATH. http://www.path.org/publications/files/TS_vaccine_stability_table.pdf.
13. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
14. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
15. Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A.M., et al. The virosome concept for influenza vaccines. Vaccine 2005, 23(Suppl.1):S26-S38.
16. Principi N., Esposito S. Adjuvanted influenza vaccines. Hum Vaccines Immunother 2012, 8:59-66.
17. Moser C., Amacker M., Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011, 10:437-446.
18. Kniskern P.J., Marburg S., Ellis R.W. Haemophilus influenzae type b conjugate vaccines. Pharm Biotechnol 1995, 6:673-694.
19. McIntyre P.B., O'Brien K.L., Greenwood B., van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet 2012, 380:1703-1711.
20. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2012, Elsevier/Saunders.
21. Sturgess A.W., Rush K., Charbonneau R.J., Lee J.I., West D.J., Sitrin R.D., et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 1999, 17:1169-1178.
22. Sweeney J.A., Sumner J.S., Hennessey J.P. Simultaneous evaluation of molecular size and antigenic stability of PNEUMOVAX 23, a multivalent pneumococcal polysaccharide vaccine. Dev Biol (Basel) 2000, 103:11-26.
23. Evans R.K., Xu Z., Bohannon K.E., Wang B., Bruner M.W., Volkin D.B. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies. JPharm Sci 2000, 89:76-87.
24. Middaugh C.R., Ramsey J.D. Analysis of cationic-lipid-plasmid-DNA complexes. Anal Chem 2007, 79:7240-7248.
25. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509-517.
26. Mbow M.L., De Gregorio E., Valiante N.M., Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
27. Lindblad E.B. Aluminium adjuvants-in retrospect and prospect. Vaccine 2004, 22:3658-3668.
28. Hem S.L., White J.L. Structure and properties of aluminum-containing adjuvants. Pharm Biotechnol 1995, 6:249-276.
29. Hem S.L., Hogenesch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007, 6:685-698.
30. Garcon N., Morel S., Didierlaurent A., Descamps D., Wettendorff M., Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs: Clin Immunother Biopharm Gene Ther 2011, 25:217-226.
31. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59-an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
32. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
33. Dey A.K., Srivastava I.K. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines 2011, 10:227-251.
34. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. JPharm Sci 2009, 98:1278-1316.
35. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010, 128:29-35.
36. Lebre F., Borchard G., de Lima M.C., Borges O. Progress towards a needle-free hepatitis B vaccine. Pharm Res 2011, 28:986-1012.
37. Kis E.E., Winter G., Myschik J. Devices for intradermal vaccination. Vaccine 2012, 30:523-538.
38. Rexroad J., Wiethoff C.M., Jones L.S., Middaugh C.R. Lyophilization and the thermostability of vaccines. Cell Preserv Technol 2002, 1:91-104.
39. Adams G.D. Lyophilization of vaccines: current trends. Methods Mol Med 2003, 87:223-244.
40. Singh M., Srivastava I.K., Chesko J., Fox C., Dutill T., Vedvick T., et al. Lyophilization and stabilization of vaccines. Development of vaccines: from discovery to clinical testing 2011, 385-397.
41. Recommendations and guidelines: vaccine administration 2013, CDC. http://www.cdc.gov/vaccines/recs/vac-admin/default.htm.
42. Kamerzell T.J., Esfandiary R., Joshi S.B., Middaugh C.R., Volkin D.B. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 2011, 63:1118-1159.
43. Inactive ingredient search for approved drug products 2013, US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
44. Meyer B.K., Ni A., Hu B., Shi L. Antimicrobial preservative use in parenteral products: past and present. JPharm Sci 2007, 96:3155-3167.
45. al-Shakhshir R.H., Regnier F.E., White J.L., Hem S.L. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995, 13:41-44.
46. Shi Y., HogenEsch H., Hem S.L. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 2001, 20:80-85.
47. Braun L.J., Eldridge A.M., Cummiskey J., Arthur K.K., Wuttke D.S. The role of adjuvant in mediating antigen structure and stability. JPharm Sci 2012, 101:1391-1399.
48. Hem S.L., HogenEsch H., Middaugh C.R., Volkin D.B. Preformulation studies-the next advance in aluminum adjuvant-containing vaccines. Vaccine 2010, 28:4868-4870.
49. Volkin D.B., Middaugh C.R. Vaccines as physically and chemically well-defined pharmaceutical dosage forms. Expert Rev Vaccines 2010, 9:689-691.
50. Morefield G.L. Arational, systematic approach for the development of vaccine formulations. AAPS J 2011, 13:191-200.
51. Hansen B., Sokolovska A., HogenEsch H., Hem S.L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007, 25:6618-6624.
52. Clapp T., Siebert P., Chen D., Jones Braun L. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. JPharm Sci 2011, 100:388-401.
53. Peek L.J., Martin T.T., Elk Nation C., Pegram S.A., Middaugh C.R. Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. JPharm Sci 2007, 96:547-557.
54. Braun L.J., Jezek J., Peterson S., Tyagi A., Perkins S., Sylvester D., et al. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine 2009, 27:4609-4614.
55. Jezek J., Chen D., Watson L., Crawford J., Perkins S., Tyagi A., et al. Aheat-stable hepatitis B vaccine formulation. Hum Vaccines 2009, 5:529-535.
56. Clausi A., Cummiskey J., Merkley S., Carpenter J.F., Braun L.J., Randolph T.W. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. JPharm Sci 2008, 97:5252-5262.
57. Clausi A.L., Merkley S.A., Carpenter J.F., Randolph T.W. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying. JPharm Sci 2008, 97:2049-2061.
58. Krause P.R. Goals of stability evaluation throughout the vaccine life cycle. Biol: J Int Assoc Biol Stand 2009, 37:369-378. discussion 421-3.
59. Metz B., van den Dobbelsteen G., van Els C., van der Gun J., Levels L., van der Pol L., et al. Quality-control issues and approaches in vaccine development. Expert Rev Vaccines 2009, 8:227-238.
60. Schofield T.L. Maintenance of vaccine stability through annual stability and comparability studies. Biol: J Int Assoc Biol Stand 2009, 37:397-402.
61. Schofield T., Krause P.R. Stability evaluation of vaccines. Biol: J Int Assoc Biol Stand 2009, 37:355.
62. Shin J., Smith D., Southern J., Knezevic I. WHO/KFDA workshop on stability evaluation of vaccines, Seoul, Korea, 23-25 April 2008. Biologicals 2009, 37:435-444. discussion 21-3.
63. Smith D., Duchene M., Egan W., Jivapaisarnpong T., Knezevic I., Pierard I., et al. Panel discussion. Biologicals 2009, 37:421-423.
64. Egan W., Schofield T. Basic principles of stability. Biologicals 2009, 37:379-386. discussion 421-3.
65. Knezevic I. Stability evaluation of vaccines: WHO approach. Biologicals 2009, 37:357-359.
66. Quality of biotechnological products: stability testing of biotechnological/biological products Q5C. ICH Harmonized Tripartite Guidueline: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 1995, 1-10.
67. Dobbelaer R., Pfleiderer M., Haase M., Griffiths E., Knezevic I., Merkle A., et al. Guidelines on stability evaluation of vaccines. Biologicals 2009, 37:424-434. discussion 1-3.
68. Pfleiderer M. Stability of vaccines - bridging from stability data to continuous safety and efficacy throughout shelf life - an always reliable approach?. Biol: J Int Assoc Biol Stand 2009, 37:364-368.
69. Griffiths E., Knezevic I. Assuring the quality and safety of vaccines: regulatory licensing and batch release. Methods Mol Med 2003, 87:353-376.
70. Levinson D.R. Vaccines for children program: vulnerabilities in vaccine management 2012, Department of Health and Human Services: Office of Inspector General.
71. McColloster P.J. US vaccine refrigeration guidelines: loose links in the cold chain. Hum Vaccines 2011, 7:574-575.
72. Organization W.H. Aide-memoire for prevention of freeze damage to vaccines 2007, 1-4.
73. Angoff R., Wood J., Chernock M., Tipping D. Visual freeze indicators on each box of vaccine are an early warning tool to identify potential for freeze damage. National Conference of American Academy of Pediatrics. San Diego, California, USA 2013.
74. Turner N., Laws A., Roberts L. Assessing the effectiveness of cold chain management for childhood vaccines. JPrim Health Care 2011, 3:278-282.
75. Rogers B., Dennison K., Adepoju N., Dowd S., Uedoi K. Vaccine cold chain: part 1. proper handling and storage of vaccine. AAOHN J 2010, 58:337-344. quiz 45-6.
76. Kartoglu U., Ganivet S., Guichard S., Aiyer V., Bollen P., Maire D., et al. Use of cool water packs to prevent freezing during vaccine transportation at the country level. PDA J Pharm Sci Technol/PDA 2009, 63:11-26.
77. Martin J.P., Lloyd J. The key role of vaccine vial monitors in routine and mass immunisation. JIndian Med Assoc 2005, 103:686-687.
78. Getting started with vaccine vial monitors 2002, World Health Organization. http://whqlibdoc.who.int/hq/2002/WHO_V%26B_02.35.pdf.
79. Kozlowski S., Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 2006, 58:707-722.
80. Kartoglu U., Milstien J. Tools and approaches to ensure quality of vaccines throughout the cold chain. Expert Rev Vaccines 2014, 13:843-854.
81. Ammann C. Stability studies needed to define the handling and transport conditions of sensitive pharmaceutical or biotechnological products. AAPS PharmSciTech 2011, 12:1264-1275.
82. Dobbelaer R., Pfleiderer M., Haase M., Griffiths E., Knezevic I., Merkle A., et al. Guidelines on stability evaluation of vaccines. Biol: J Int Assoc Biol Stand 2009, 424-434. discussion 1-3.
83. Ammann C. How best to use stability data for handling of time and temperature sensitive products http://vimeo.com/514413212012.
84. Smith D., Ferguson M., Krause P.R., Wu T., Baca-Estrada M., Christoph C., et al. WHO/Health Canada Drafting Group Meeting on Scientific and Regulatory Considerations on the Stability Evaluation of Vaccines under Controlled Temperature Chain. WHO/ Health Canada Drafting Group Meeting on Scientific and Regulatory Considerations on the Stability Evaluationof Vaccines under Controlled Temperature Chain. National Hotel and Suites 2012, World Health Organization, Ottawa, Canada.
85. Pierard I., Spelte G., Le Tallec D., Duchene M. Consideration on a few aspects of the stability studies post licensure. Biol: J Int Assoc Biol Stand 2009, 37:403-406. discussion 21-3.
86. Cohen V., Jellinek S.P., Teperikidis L., Berkovits E., Goldman W.M. Room-temperature storage of medications labeled for refrigeration. Am J Health-system Pharm AJHP: Off J Am Soc Health-System Pharm 2007, 64:1711-1715.
87. Toback S.L., Susla G.M., Darling A.J., Ambrose C.S. Clinical guidance on the use of live attenuated influenza vaccine after inadvertent freezing and warming. JPediatr Nurs 2012, 27:163-167.
88. Coenen F., Tolboom J.T.B.M., Frijlink H.W. Stability of influenza sub-unit vaccine. Does a couple of days outside the refrigerator matter?. Vaccine 2006, 24:525-531.
89. Le Tallec D., Doucet D., Elouahabi A., Harvengt P., Deschuyteneer M., Deschamps M. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccines 2009, 5:467-474.
90. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl.2):B40-B45.
91. Holte Ø., Horvat M. Uniformity of dosage units using large sample sizes. Pharm Technol 2012, 36:118-122.
92. Kartoglu U., Ozgüler N.K., Wolfson L.J., Kurzatkowski W. Validation of the shake test for detecting freeze damage to adsorbed vaccines. Bull World Health Organ 2010, 88:624-631.
93. Kurzatkowski W., Kartoglu U., Staniszewska M., Gorska P., Krause A., Wysocki M.J. Structural damages in adsorbed vaccines affected by freezing. Biologicals 2013, 41:71-76.
94. Immunization systems and policy 2013, World Health Organization. http://www.who.int/immunization_delivery/systems_policy/en/.
95. Glezen W.P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982, 4:25-44.
96. Amorij J.-P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L.J. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm Res 2008, 25:1256-1273.
97. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports 2010, 1-62. Centers for Disease Control.
98. Wright P.F., Webster R.G. Orthomyxoviruses. Fields virology 2001, 1:1533-1579.
99. Grohskopf L., Uyeki T., Bresee J., Cox N. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morbidity Mortal Wkly Rep 2012, 613-618.
100. Wang K., Holtz K.M., Anderson K., Chubet R., Mahmoud W., Cox M.M.J. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24:2176-2185.
101. Iyer V., Liyanage M.R., Shoji Y., Chichester J.A., Jones R.M., Yusibov V., et al. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen. Hum vaccines Immunother 2012, 8:453-464.
102. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA: J Am Med Assoc 2007, 297:1577-1582.
103. CB B., R W. Inactivated influenza vaccine. Vaccines 2008, 259-290. Saunders, Philadelphia, PA. P. SA, O. WA, O. PA (Eds.).
104. RB B., R W. Influenza vaccine-live. Vaccines 2008, 291-310. Saunders. P. SA, O. WA, O. PA (Eds.).
105. Lambert L.C., Fauci A.S. Influenza vaccines for the future. NEngl J Med 2010, 363:2036-2044.
106. Flint S.J., Enquist L.W., Racaniello V.R. Principles of virology 2009, Amer Society for Microbiology.
107. Hickling J., E D.H. Areview of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness 2006, Geneva, Switzerland. http://www.who.int/vaccine_research/diseases/influenza/Flu_vacc_manuf_tech_report.pdf.
108. Schild G.C., Wood J.M., Newman R.W. Asingle-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Bull World Health Organ 1975, 52:223-231.
109. Luykx D.M.A.M., Casteleijn M.G., Jiskoot W., Westdijk J., Jongen P.M.J.M. Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material. Eur J Pharm Sci Off J Eur Fed Pharm Sci 2004, 23:65-75.
110. Kissmann J., Joshi S.B., Haynes J.R., Dokken L., Richardson C., Middaugh C.R. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers. JPharm Sci 2011, 100:634-645.
111. Hickey J.M., Holtz K.M., Manikwar P., Joshi S.B., McPherson C.E., Buckland B., et al. Mechanism of a decrease in potency for the recombinant influenza a virus hemagglutinin H3 antigen during storage. JPharm Sci 2014, 103:821-827.
112. Griffin D.E., Pan C.H. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009, 330:191-212.
113. Streble. Measles vaccine. Vaccines 2008, 353-398. Saunders, Philadelphia.
114. Wolfson L.J., Strebel P.M., Gacic-Dobo M., Hoekstra E.J., McFarland J.W., Hersh B.S., et al. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007, 369:191-200.
115. Global goal to reduce measles deaths in children surpassed 2007, World Health Organization, World Health Organization, Joint News Release by the Measles Initiative/WHO/NICEF/ARC/CDC/UNF. http://www.who.int/mediacentre/news/releases/2007/pr02/en/index.html.
116. Kissmann J., Ausar S.F., Rudolph A., Braun C., Cape S.P., Sievers R.E., et al. Stabilization of measles virus for vaccine formulation. Hum Vaccines 2008, 4:350-359.
117. Ohtake S., Martin R.A., Yee L., Chen D., Kristensen D.D., Lechuga-Ballesteros D., et al. Heat-stable measles vaccine produced by spray drying. Vaccine 2010, 28:1275-1284.
118. Coates A.L., Tipples G., Leung K., Gray M., Louca E. Vaccine WPDGfMA. How many infective viral particles are necessary for successful mass measles immunization by aerosol?. Vaccine 2006, 24:1578-1585.
119. Staff P. 2004 Physicians' desk reference 2003, Physician's Desk Reference (PDR).
120. Watson J.C., Hadler S.C., Dykewicz C.A., Reef S., Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP) 1998, vol. 47. No. RR-8. DTIC Document.
121. Bernstein H.H., Eves K., Campbell K., Black S.B., Twiggs J.D., Reisinger K.S., et al. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). Pediatrics 2007, 119:e1299-e1305.
122. Chun B.-H., Lee Y.K., Lee B.C., Chung N. Development of a varicella virus vaccine stabilizer containing no animal-derived component. Biotechnol Lett 2004, 26:807-812.
123. Liska V., Bigert S.A., Bennett P.S., Olsen D., Chang R., Burke C.J. Evaluation of a recombinant human gelatin as a substitute for a hydrolyzed porcine gelatin in a refrigerator-stable Oka/Merck live varicella vaccine. Jimmune Based Ther Vaccines 2007, 5:4.
124. Cohen B.J., Audet S., Andrews N., Beeler J. Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 2007, 26:59-66. test Wwgomprn.
125. Arya S.C., Agarwal N. Efficacy of measles vaccine interlinked with potency and storage. Acta Trop 2004, 90:223-225.
126. Rizzo Ed, Pereira CAdB., Fang F.L.W., Takata C.S., Tenório E.C.N., Pral M.M., et al. Fotossensibilidade e termoestabilidade de vacinas contra o sarampo (cepa Biken CAM-70) liofilizadas e/ou reconstituídas para administração. Revista de Saúde Pública 1990, 24:51-59.
127. Ren Q., Xiong H., Li Y., Xu R., Zhu C. Evaluation of an outside-the-cold-chain vaccine delivery strategy in remote regions of western China. Public Health Rep 2009, 124:745-750.
128. Acu F.D., Adedeji A.A., Esan J.S., Odusanya O.G. Live viral vaccine potency: an index for assessing the cold chain system. Public health 1996, 110:325-330.
129. Oliveira S.A., Homma A., Mahul D.C., Loureiro M.L., Camillo-Coura L. Evaluation of the conditions of storage of measles vaccine at the Public Health Units of Niteroi and São Gonçalo, State of Rio de Janeiro. Revista do Instituto de Medicina Tropical de São Paulo 1991, 33:313-318.
130. Oliveira S.A., Loureiro M.L., Kiffer C.R., Maduro L.M. Re-evaluation of the basic procedures involved in the storage of measles vaccine in public health units of the municipality of Niterói, State of Rio de Janeiro, Brazil. Revista da Sociedade Brasileira de Medicina Trop 1993, 26:145-149.
131. Burger J.L., Cape S.P., Braun C.S., McAdams D.H., Best J.A., Bhagwat P., et al. Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine. JAerosol Med Pulm Drug Deliv 2008, 21:25-34.
132. Cutts F.T., Clements C.J., Bennett J.V. Alternative routes of measles immunization: a review. Biol: J Int Assoc Biol Stand 1997, 25:323-338.
133. Wong-Chew R.M., Islas-Romero R., García-García MdL., Beeler J.A., Audet S., Santos-Preciado J.I., et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 2006, 24:683-690.
134. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010, 2:19ra2.
135. Wadman M. Efforts to improve vaccine stabilization heat up. Nat Med 2009, 15:1232.
136. Wiggan OaN., Livengood J.A., Silengo S.J., Kinney R.M., Osorio J.E., Huang C.Y.-H., et al. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine 2011, 29:7456-7462.
137. Zhang J., Pritchard E., Hu X., Valentin T., Panilaitis B., Omenetto F.G., et al. Stabilization of vaccines and antibiotics in silk and eliminating the cold chain. Proc Natl Acad Sci U S A 2012, 109:11981-11986.
138. Atkinson W., Wolfe S., Hamborsky J. Epidemiology and prevention of vaccine-preventable diseases 2011, Public Health Foundation.
139. Rueckert R. Picornaviridae: the viruses and their replication. Fields Virol 1996, 1:609-654.
140. Toyoda H., Kohara M., Kataoka Y., Suganuma T., Omata T., Imura N., et al. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. JMol Biol 1984, 174:561-585.
141. Graf H. Manufacturing and supply of monovalent oral polio vaccines. Biol: J Int Assoc Biol Stand 2006, 34:141-144.
142. Furesz J. Developments in the production and quality control of poliovirus vaccines - historical perspectives. Biol: J Int Assoc Biol Stand 2006, 34:87-90.
143. Prevots D.R., Burr R.K., Sutter R.W., Murphy T.V. Advisory Committee on Immunization P. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports: Morbidity and mortality weekly report Recommendations and reports 2000, 49:1-22. Centers for Disease Control, quiz CE1-7.
144. Melnick J.L. Thermostability of poliovirus and measles vaccines. Dev Biol Stand 1996, 87:155-160.
145. Moynihan M., Petersen I. The durability of inactivated poliovirus vaccine: studies on the stability of potency invivo and invitro. JBiol Stand 1982, 10:261-268.
146. Rombaut B., Verheyden B., Andries K., Boeyé A. Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation. JVirol 1994, 68:6454-6457.
147. Wallis C., Melnick J.L. Magnesium chloride enhancement of cell susceptibility to poliovirus. Virology 1962, 16:122-132.
148. Wu R., Georgescu M.M., Delpeyroux F., Guillot S., Balanant J., Simpson K., et al. Thermostabilization of live virus vaccines by heavy water (D2O). Vaccine 1995, 13:1058-1063.
149. Sen A., Balamurugan V., Rajak K.K., Chakravarti S., Bhanuprakash V., Singh R.K. Role of heavy water in biological sciences with an emphasis on thermostabilization of vaccines. Expert Rev Vaccines 2009, 8:1587-1602.
150. Chen C.H., Wu R., Roth L.G., Guillot S., Crainic R. Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2. Arch Biochem Biophys 1997, 342:108-116.
151. Volkin D.B., Burke C.J., Marfia K.E., Oswald C.B., Wolanski B., Middaugh C.R. Size and conformational stability of the hepatitis A virus used to prepare VAQTA, a highly purified inactivated vaccine. JPharm Sci 1997, 86:666-673.
152. Milstien J.B., Lemon S.M., Wright P.F. Development of a more thermostable poliovirus vaccine. JInfect Dis 1997, 175(Suppl.1):S247-S253.
153. Verheyden B., Andries K., Rombaut B. Capsid and RNA stabilisation of the oral polio vaccine. Vaccine 2001, 19:1899-1905.
154. Samant Y., Lanjewar H., Parker D., Block L., Tomar G.S., Stein B. Evaluation of the cold-chain for oral polio vaccine in a rural district of India. Public Health Reports (Washington, DC: 1974) 2007, 122:112-121.
155. Halm A., Yalcouyé I., Kamissoko M., Keïta T., Modjirom N., Zipursky S., et al. Using oral polio vaccine beyond the cold chain: a feasibility study conducted during the national immunization campaign in Mali. Vaccine 2010, 28:3467-3472.
156. Zipursky S., Boualam L., Cheikh D.O., Fournier-Caruana J., Hamid D., Janssen M., et al. Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad. Vaccine 2011, 29:5652-5656.
157. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. Amathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
158. Chang J.J., Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007, 85:16-23.
159. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev MMBR 2000, 64:51-68.
160. Seeger C., Mason W.S. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000, 64:51-68.
161. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
162. Zuckerman J.N. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. JMed Virol 2006, 78:169-177.
163. Adamowicz P., Chabanier G., Hyafil F., Lucas G., Prunet P., Reculard P., et al. Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation. Vaccine 1984, 2:209-214.
164. Josefsberg J.O., Buckland B. Vaccine process technology. Biotechnol Bioeng 2012, 109:1443-1460.
165. Zhao Q., Wang Y., Abraham D., Towne V., Kennedy R., Sitrin R.D. Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment. Biochem Biophys Res Commun 2011, 408:447-453.
166. Kobayashi M., Asano T., Ohfune K., Kato K. Characterization of two differently glycosylated molecular species of yeast-derived hepatitis B vaccine carrying the pre-S2 region. JBiotechnol 1992, 26:155-162.
167. Zhao Q., Wang Y., Freed D., Fu T.-M., Gimenez J.A., Sitrin R.D., et al. Maturation of recombinant hepatitis B virus surface antigen particles. Hum Vaccines 2006, 2:174-180.
168. ® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. Vaccine 2011, 29:7936-7941.
169. Hammond G.W., Parker J., Mimms L., Tate R., Sekla L., Minuk G. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines. Vaccine 1991, 9:97-100.
170. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007, 6:133-140.
171. Alderson M.R., McGowan P., Baldridge J.R., Probst P. TLR4 agonists as immunomodulatory agents. JEndotoxin Res 2006, 12:313-319.
172. Giffroy D., Mazy C., Duchene M. Validation of a new ELISA method for invitro potency assay of hepatitis B-containing vaccines. Pharmeuropa bio/the Biol Stand Programme, EDQM 2006, 2006:7-14.
173. Mulder A.M., Carragher B., Towne V., Meng Y., Wang Y., Dieter L., et al. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PloS One 2012, 7:e33235.
174. Van Damme P., Cramm M., Safary A., Vandepapelière P., Meheus A. Heat stability of a recombinant DNA hepatitis B vaccine. Vaccine 1992, 10:366-367.
175. Sanyal G., Shi L. Areview of multiple approaches towards an improved hepatitis B vaccine. Expert Opin Ther Patents 2009, 19:59-72.
176. Chen D., Tyagi A., Carpenter J., Perkins S., Sylvester D., Guy M., et al. Characterization of the freeze sensitivity of a hepatitis B vaccine. Hum Vaccines 2009, 5:26-32.
177. Hipgrave D.B., Tran T.N., Huong V.M., Dat D.T., Nga N.T., Long H.T., et al. Immunogenicity of a locally produced hepatitis B vaccine with the birth dose stored outside the cold chain in rural Vietnam. Am J Trop Med Hyg 2006, 74:255-260.
178. Nelson C.M., Wibisono H., Purwanto H., Mansyur I., Moniaga V., Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 2004, 82:99-105.
179. Edstam J.S., Dulmaa N., Nymadawa P., Rinchin A., Khulan J., Kimball A.M. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. Prev Med 2002, 34:207-214.
180. Edstam J.S., Dulmaa N., Tsendjav O., Dambasuren B., Densmaa B. Exposure of hepatitis B vaccine to freezing temperatures during transport to rural health centers in Mongolia. Prev Med 2004, 39:384-388.
181. Davaalkham D., Ojima T., Wiersma S., Lkhagvasuren T., Nymadawa P., Uehara R., et al. Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. JEpidemiol Commun Health 2007, 61:578-584.
182. Kristensen D., Chen D., Cummings R. Vaccine stabilization: research, commercialization, and potential impact. Vaccine 2011, 29:7122-7124.
183. Chen D., Zehrung D. Desirable attributes of vaccines for deployment in low-resource settings. JPharm Sci 2013, 102:29-33.
184. Kristensen D., Chen D. Stabilization of vaccines: Lessons learned. Hum Vaccin 2010, 6:229-231.
185. Santoli J.M., Peter G., Arvin A.M., Davis J.P., Decker M.D., Fast P., et al. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA 2003, 290:3122-3128.
186. Peter G., des Vignes-Kendrick M., Eickhoff T.C., Fine A., Galvin V., Levine M.M., et al. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 1999, 104:942-950.
187. Orenstein W.A., Douglas R.G., Rodewald L.E., Hinman A.R. Immunizations in the United States: success, structure, and stress. Health Aff 2005, 24:599-610.
188. Response USHHSASfP. The Public Health Emergency Medical Countermeasures Enterprise review: transforming the enterprise to meet long-range national needs 2010, Assistant Secretary.
189. Braun L.J., Tyagi A., Perkins S., Carpenter J., Sylvester D., Guy M., et al. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 2009, 27:72-79.
190. Maddux N.R., Joshi S.B., Volkin D.B., Ralston J.P., Middaugh C.R. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci. 2011, 100:4171-4197.
191. Wang T., Joshi S.B., Kumru O.S., Telikepalli S., Middaugh C.R., Volkin D.B. Case studies applying biophysical techniques to better characterize protein aggregates and particulates of varying size. Biophysics for therapeutic protein development 2013, 205-243. Springer.
192. Ausar S.F., Chan J., Hoque W., James O., Jayasundara K., Harper K. Application of extrinsic fluorescence spectroscopy for the high throughput formulation screening of aluminum-adjuvanted vaccines. JPharm Sci 2011, 100:431-440.
193. Schlehuber L.D., McFadyen I.J., Shu Y., Carignan J., Duprex W.P., Forsyth W.R., et al. Towards ambient temperature-stable vaccines: the identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay. Vaccine 2011, 29:5031-5039.
194. Broker M., Dull P.M., Rappuoli R., Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009, 27:5574-5580.
195. Foldvari M. HPV infections: can they be eradicated using nanotechnology?. Nanomedicine 2012, 8:131-135.
196. Medina R.A., Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol 2011, 9:590-603.
197. Belnap D.M., Filman D.J., Trus B.L., Cheng N., Booy F.P., Conway J.F., et al. Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus. JVirol 2000, 74:1342-1354.
198. Schneider-Schaulies S., ter Meulen V. Measles virus and immunomodulation: molecular bases and perspectives. Expert Rev Mol Med 2002, 4:1-18.
199. Schofield T.L. Vaccine stability study design and analysis to support product licensure. Biol: J Int Assoc Biol Stand 2009, 37:387-396. discussion 421-3.
200. Shaw M.L., Stone K.L., Colangelo C.M., Gulcicek E.E., Palese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008, 4:e1000085.
201. High-Throughput Fluorescence Focus Assay for Live Virus-Based Vaccine Development. In: Devices M, editor. Application Note. http://www.moleculardevices.com/Documents/general-documents/mkt-appnotes/hca-appnotes/ImageXpress%20Velos%20App%20Note%2013.pdf.
202. Krenn B.M., Egorov A., Romanovskaya-Romanko E., Wolschek M., Nakowitsch S., Ruthsatz T., et al. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PloS One 2011, 6:e18577.
203. Feshchenko E., Rhodes D.G., Felberbaum R., McPherson C., Rininger J.A., Post P., et al. Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol 2012, 12:77.
204. Vodeiko G.M., Weir J.P. Determination of H5N1 vaccine potency using reference antisera from heterologous strains of influenza. Influenza Other Respir Viruses 2012, 6:176-187.
205. Fukuda A., Sengun F., Sarpay H.E., Konobe T., Saito S., Umino Y., et al. Parameters for plaque formation in the potency assay of Japanese measles vaccines. JVirol Methods 1996, 61:1-6.
206. Cho S.P., Lee B., Min M.K. Recombinant polioviruses expressing hepatitis B virus-specific cytotoxic T-lymphocyte epitopes. Vaccine 2000, 18:2878-2885.
207. Hasija M., Li L., Rahman N., Ausar S.F. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine: Dev Ther 2013, 3:11-33.